ISCT 2021 | MSCs for type I diabetes

Lindsay Davies, PhD, Karolinska Institutet & NextCell Pharma AB, Huddinge, Sweden, describes the rationale behind mesenchymal stromal cell (MSC)-based therapy for Type I diabetes (T1D). Dr Davies describes a strategy that involves the administration of a single dose of MSCs, with the aim of re-educating of the patient’s immune system and restoring beta cell function, thus reducing the co-morbidities associated with late-stage T1D, such as chronic wounds. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.